atyr
pharma
participate
roth
capital
partners
webinar
therapeutics
development
october
san
diego
globe
newswire
atyr
pharma
nasdaq
life
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
biological
pathways
today
announced
sanjay
shukla
president
chief
executive
officer
participate
panel
titled
immune
modulators
ameliorate
part
roth
capital
partners
webinar
therapeutics
development
october
details
event
follows
event
roth
capital
partners
webinar
therapeutics
development
panel
immune
modulators
ameliorate
date
wednesday
october
time
eastern
time
registration
webinar
available
investor
section
company
website
replay
live
webcast
available
company
website
following
event
atyr
atyr
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
biological
pathways
atyr
research
development
efforts
concentrated
newly
discovered
area
biology
extracellular
functionality
signaling
pathways
trna
synthetases
atyr
built
global
intellectual
property
estate
directed
potential
pipeline
protein
compositions
derived
trna
synthetase
genes
extracellular
targets
atyr
primary
focus
product
candidate
binds
receptor
designed
immune
engagement
inflammatory
lung
diseases
information
please
visit
http
contact
ashlee
dunston
investor
relations
atyr
pharma
adunston
